Immunization against Hepatitis E
- PMID: 29530951
- PMCID: PMC6211382
- DOI: 10.1101/cshperspect.a032573
Immunization against Hepatitis E
Abstract
Soon after the 1991 molecular cloning of hepatitis E virus (HEV), recombinant viral capsid antigens were expressed and tested in nonhuman primates for protection against liver disease and infection. Two genotype 1 subunit vaccine candidates entered clinical development: a 56 kDA vaccine expressed in insect cells and HEV 239 vaccine expressed in Escherichia coli Both were highly protective against hepatitis E and acceptably safe. The HEV 239 vaccine was approved in China in 2011, but it is not yet prequalified by the World Health Organization, a necessary step for introduction into those low- and middle-income countries where the disease burden is highest. Nevertheless, the stage is set for the final act in the hepatitis E vaccine story-policymaking, advocacy, and pilot introduction of vaccine in at-risk populations, in which it is expected to be cost-effective.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.
References
-
- Andjaparidze AG, Balaian MS, Savinov AP, Braginskiĭ DM, Poleshchuk VF, Zamyatina NA. 1986. Reproduction in monkeys of non-A, non-B hepatitis transmitted via the fecal and oral routes. Vopr Virusol 31: 73–81. - PubMed
-
- Arankalle VA, Ticehurst J, Sreenivasan MA, Kapikian AZ, Popper H, Pavri KM, Purcell RH. 1988. Aetiological association of a virus-like particle with enterically transmitted non-A, non-B hepatitis. Lancet 1: 550–554. - PubMed
-
- Balayan MS, Andjaparidze AG, Savinskaya SS, Ketiladze ES, Braginsky DM, Savinov AP, Poleschuk VF. 1983. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 20: 23–31. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical